Explore the NIHProtocol Details
Use of Granulocyte Colony Stimulating Factor (G-CSF) Mobilized Leukapheresis Collections from Healthy Volunteers to Develop Improved Methods of Stem Cell and Lymphocyte Selection for Allogeneic Transplantation
This study is currently recruiting participants.
Summary | Eligibility | Citations | Contacts
Summary
Number |
96-H-0049 |
Sponsoring Institute |
National Heart, Lung and Blood Institute (NHLBI) |
Recruitment Detail |
Type: Participants currently recruited/enrolled |
Referral Letter Required |
Yes |
Population Exclusion(s) |
Children |
Special Instructions |
Currently Not Provided |
Keywords |
G-CSF; |
Recruitment Keyword(s) |
Normal Volunteer |
Condition(s) |
Graft vs Host Disease; |
Investigational Drug(s) |
None |
Investigational Device(s) |
None |
Intervention(s) |
Drug: G-CSF |
Supporting Site |
|
One serious reaction complicating bone marrow transplants is referred to as graft-versus-host disease (GVHD). GVHD is a potentially fatal incompatibility reaction. The reaction is caused by antigens found on the cells of the patient that are not present on the cells of the donor. The antigens are recognized by transplanted white blood cells (lymphocytes). These lymphocytes begin attacking the recipient's cells and tissues and may lead to death.
In order to avoid GVHD, researchers have developed a technique using peripheral blood instead of bone marrow that allows transplantation of stem cells and removal of lymphocytes. Stem cells are the cells responsible for returning blood cell production to normal. Lymphocytes are the white blood cells that can cause GVHD.
The technique requires two steps. In the first step blood cells are collected from donors who have received doses of a growth factor. The growth factor (granulocyte colony stimulating factor) is designed to increase the production of donor stem cells.
In the second step white blood cell lymphocytes are removed from the collected blood, leaving only the stem cells.
The main goal of this study is to develop and improve the method of processing cells that are collected after stimulation with growth factor (G-CSF), by removing the white blood cell lymphocytes which can cause graft-versus-host disease (GVHD) while keeping the stem cells necessary for healthy blood cell building. In addition, researchers are interested in studying whether giving G-CSF has an effect on lymphocyte function, which may influence the immune reactions occurring in bone marrow transplantation.
Eligibility
INCLUSION CRITERIA:
Healthy healthy individual aged between 18 and 60 years.
No active infection or history of recurrent infection.
Normal renal function: creatinine less than 1.5 mg/dl, proteinuria less than 1+.
Normal liver function: bilirubin less than 1.5 mg/dl, transaminase within normal limit.
Normal blood count: WBC 3000 to 10,000/mm(3), granulocytes greater than 1500/mm(3), platelets greater than 150,000/mm(3), hemoglobin greater than 12.5 g/dl, MCV and MCHC normal.
Normal cardiovascular function, no history of chest pain, myocardial infarction, peripheral vascular disease, transient ischemic attack, or stroke.
Healthy female subjects of childbearing age should have a negative serum pregnancy test within one week of beginning G-CSF administration.
Female subjects should not be lactating.
Subject must be eligible for normal blood donation. He or she must be tested negative for syphilis (RPR), hepatitis B and C (HBsAg, Anti HBc, Anti HCV), HIV and HTLV 1.
Subject must be able to comprehend the investigational nature of the study and provide informed consent to participate in this protocol.
Antecubital veins must be adequate for peripheral access during apheresis. Potential participants must be screened by an apheresis nurse to check venous access before protocol entry.
EXCLUSION CRITERIA:
Active viral, bacterial, fungal or parasite infection.
Female with positive pregnancy test or lactating.
History autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus.
History of cancer excluding squamous carcinoma of the skin.
History of any hematologic disorders.
History of cardiovascular disease or related symptoms such as chest pain, shortness of breath, history of cerebrovascular disease.
Any positive serum screening test as listed in eligibility.
Allergy to G-CSF or bacterial E coli products.
Administration of NSAID within 10 days of starting protocol.
History of G-CSF administration and leukapheresis within past 3 months.
Citations:
Contacts:
Principal Investigator |
Referral Contact |
For more information: |
| Cynthia E. Dunbar, M.D. National Heart, Lung and Blood Institute (NHLBI) National Institutes of Health Building 10 Room 4-5132 10 Center Drive Bethesda, Maryland 20892 (301) 496-5093 dunbarc@nhlbi.nih.gov |
Cynthia E. Dunbar, M.D. National Heart, Lung and Blood Institute (NHLBI) National Institutes of Health Building 10 Room 4-5132 10 Center Drive Bethesda, Maryland 20892 (301) 496-5093 dunbarc@nhlbi.nih.gov |
Patient Recruitment and Public Liaison Office Building 61 10 Cloister Court Bethesda, Maryland 20892-4754 Toll Free: 1-800-411-1222 TTY: 301-594-9774 (local),1-866-411-1010 (toll free) Fax: 301-480-9793 prpl@mail.cc.nih.gov |
Clinical Trials Number:
NCT00001529
QUESTIONS?
Contact the Patient Recruitment and Public Liaison Office for:
- Details on how to participate in a study
- Details on how to refer a patient to a study
NIH Clinical Studies Information Request
Contact the Office of Communications for:
- General information about the NIH Clinical Center
Contact the Department Clinical Research Informatics, (DCRI) for:
- Technical questions about Adobe Acrobat and the PDF format
- Technical questions about this web server
